DAVALINTIDE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19935749 | https://www.ncbi.nlm.nih.gov/pubmed/21733060 | https://clinicaltrials.gov/ct2/show/NCT00785408 | http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NDc5MTh8Q2hpbGRJRD0tMXxUeXBlPTM=&t=1

Davalintide (AC-2307) is a second-generation mimetic of a pancreatic peptide hormone amylin, developed by Amylin Pharmaceuticals. In preclinical models, davalintide possessed enhanced pharmacological properties and was able to reduce food intake. Safety, tolerability, and effect on body weight of subcutaneous davalintide were investigated in obese or overweight subjects. The results of the clinical trial were not reported, but Amylin decided to discontinue davalintide in 2010.

Originator

Approval Year

Substance Class	Protein Created by `admin` on `Sat Dec 16 00:36:44 GMT 2023` Edited by `admin` on `Sat Dec 16 00:36:44 GMT 2023`
Protein Sub Type
Sequence Type	COMPLETE
Record UNII	668U999F9T
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DAVALINTIDE

Official Name

English

AC-2307

Code

English

davalintide [INN]

Common Name

English

AC2307

Code

English

DAVALINTIDE [USAN]

Common Name

English

L-LYSYL-DES-2-L-SERINE-(4-L-THREONINE(L>T),5-L-ALANINE(S>A),11-L-ARGININE(K>R),18-L-ARGININE(K>R),30-L-ASPARAGINE(G>N),32-L-TYROSINE(P>Y))CALCITONIN-1 ONCORHYNCHUS KETA (CHUM SALMON), CALCITONIN-1 PRECURSOR-(83-114)-PEPTIDAMIDE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29711